HealthCor Management L.P. decreased its holdings in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 90.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 101,000 shares of the biotechnology company’s stock after selling 909,930 shares during the quarter. HealthCor Management L.P.’s holdings in Five Prime Therapeutics were worth $2,214,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in FPRX. Victory Capital Management Inc. increased its holdings in shares of Five Prime Therapeutics by 73.5% in the fourth quarter. Victory Capital Management Inc. now owns 924,190 shares of the biotechnology company’s stock valued at $20,258,000 after purchasing an additional 391,550 shares in the last quarter. Rock Springs Capital Management LP boosted its position in shares of Five Prime Therapeutics by 95.2% during the fourth quarter. Rock Springs Capital Management LP now owns 425,000 shares of the biotechnology company’s stock worth $9,316,000 after purchasing an additional 207,300 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Five Prime Therapeutics during the fourth quarter worth $4,446,000. AXA bought a new position in shares of Five Prime Therapeutics during the third quarter worth $5,441,000. Finally, RTW Investments LP bought a new stake in Five Prime Therapeutics in the 4th quarter valued at $2,200,000. Hedge funds and other institutional investors own 74.94% of the company’s stock.
Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) opened at $19.30 on Monday. Five Prime Therapeutics Inc has a 52-week low of $17.01 and a 52-week high of $48.87. The company has a market cap of $672.81, a PE ratio of -3.59 and a beta of 3.33.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.